Antibody responses to the first four doses of SARS-CoV-2 vaccine in patients with IBD
A CITF-funded study published in The Lancet Gastroenterology & Hepatology by Drs. Gilaad Kaplan (University of Calgary) and Sasha Bernatsky (McGill University) on behalf of the STOP COVID-19 in IBD Research Group, showed a robust antibody response was achieved in individuals with IBD after the fourth dose of COVID-19 vaccine, similar in magnitude to that which followed the third dose.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed